Skip to main content
. 2020 Jan 24;12(2):1577–1590. doi: 10.18632/aging.102701

Figure 1.

Figure 1

Circulating tumor DNA (ctDNA) gene mutation profiles for MBC patients who progressed after early-line therapy and had PIK3CA mutations in kinase domain (PIK3CA–KD, A) helix domain (PIK3CA–HD, B), other region (PIK3CA–OD, C) and other PI3K/AKT pathway aberrations (P/A, D).